UCB, a Brussels, Belgium-based bio/pharmaceutical company, has announced plans to build a new US-based biomanufacturing facility and to scale up its partnerships with US-based CDMOs.  

The company says that the new facility will be used to make products for the US market and that it is currently undertaking a feasibility study to determine the location for the US facility. Since 2017, the company says it has expanded its US workforce by 73% to 2,000 employees and has made $4.5 billion in acquisitions and capital investments that have strengthened its position in the US. Since 2017, the company has received 15 US Food and Drug Administration approvals or indication expansions, which include eight of which came over the past two years (as reported on June 12, 2025).  

The new facility is expected to create around 300 permanent direct jobs in biologics manufacturing and more than 500 jobs during construction. The company has not disclosed the level of its investment in the new facility but estimates that the new facility will have an total economic impact of $5 billion.  

Source: UCB